Review reports fewer deep infections with topical antibiotic powder after fracture surgery
The analysis found fewer fracture-related infections, especially those caused by gram-positive bacteria, but the evidence remains limited.
Moderate evidenceReviewSome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Researchers combined results from randomized controlled trials comparing intraoperative topical vancomycin powder with no vancomycin, placebo, or standard care in people having surgery for upper- or lower-limb fractures. The review examined infection rates as well as complications such as nonunion, wound-healing problems, kidney impairment, and antimicrobial resistance.
The pooled results were associated with a lower rate of fracture-related infection or deep surgical-site infection among people who received topical vancomycin. The analysis did not find significant differences in superficial infections, nonunion, wound healing, or other reported complications. The findings do not establish that the powder is suitable for every type of surgery or patient.
The question reviewed
This systematic review evaluated whether vancomycin powder placed at the surgical site during limb-fracture surgery could reduce fracture-related infection or deep surgical-site infection when added to standard systemic antibiotic prevention. The researchers searched Medline, EMBASE, and Cochrane CENTRAL in February 2026 and included five randomized controlled trials involving 1,373 patients. The review also examined infection-causing organisms, antimicrobial resistance, superficial infection, nonunion, revision surgery, wound problems, kidney impairment, and other complications.
What the review concluded
Compared with control care, topical vancomycin was associated with a lower risk of fracture-related or deep surgical-site infection: risk ratio 0.64, with a 95% confidence interval from 0.43 to 0.96. Infections caused by gram-positive organisms were also less frequent in the vancomycin groups: risk ratio 0.41, with a 95% confidence interval from 0.24 to 0.71. The review found no identified difference in infections caused by gram-negative or resistant organisms. It also found no statistically significant differences in superficial surgical-site infection, nonunion, wound-healing problems, other reported complications, or kidney toxicity. A lack of a statistically significant difference does not show that the treatments are equivalent for these outcomes.
Who this may apply to
The findings may be relevant to people similar to those studied: patients undergoing surgical treatment for upper- or lower-limb fractures. They may not apply to other types of surgery, people with different clinical characteristics, or settings that use different systemic antibiotics or surgical techniques. This review does not by itself determine what should be used for any individual patient, and it does not provide evidence about topical vancomycin in non-fracture operations.
What this could mean
Fracture-related infections can lead to additional illness and further surgery. These findings suggest that topical vancomycin may have a role as an addition to standard systemic antibiotic prevention during some limb-fracture operations, particularly for gram-positive infections. However, the results are based on a small body of research, and the review does not establish the balance of benefits, harms, antibiotic-resistance effects, or costs for all patients or surgical settings.
Limitations & evidence assessment
Only five trials, involving 1,373 participants, were available, and the authors described the evidence as limited by small sample sizes and a lack of high-quality randomized controlled trials. The abstract provides no detailed information about differences between the trials, such as the types of fractures, operations, follow-up periods, or vancomycin methods, so the consistency of the results across settings is uncertain. The review could not identify differences in some less common outcomes, including resistant infections and kidney toxicity, because the studies may not have been large enough to assess them reliably. The abstract also states that a large definitive trial is needed, including to assess cost-effectiveness.
Why this evidence level: This was a systematic review of randomized controlled trials involving people undergoing limb-fracture surgery. However, only five studies with 1,373 participants were included, and the authors noted that the trials were limited in quality and size, so the overall certainty is not treated as high.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Bone & Joint Open · 2026 · DOI: 10.1302/2633-1462.710.bjo-2026-0126.r1
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
